Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SML0277

Sigma-Aldrich

Methylnaltrexone bromide

≥97% (HPLC)

Synonym(s):

17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium bromide, MNTX, Methylnaltrexonium, Mrz-2663, N-Methylnaltrexone, Naltrexone MB, Quaternary ammonium naltrexone

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$113.00
25 MG
$617.00

$113.00


Check Cart for Availability

Request a Bulk Order

Select a Size

Change View
5 MG
$113.00
25 MG
$617.00

About This Item

Empirical Formula (Hill Notation):
C21H26NO4 · Br
CAS Number:
Molecular Weight:
436.34
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

$113.00


Check Cart for Availability

Request a Bulk Order

Quality Level

assay

≥97% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: ≥5 mg/mL

shipped in

wet ice

storage temp.

−20°C

SMILES string

[Br-].C[N@+]1(CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35)CC6CC6

InChI

1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1

InChI key

IFGIYSGOEZJNBE-KNLJMPJLSA-N

Gene Information

human ... OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

General description

Methylnaltrexone does not cross blood brain barrier and does not affect the opioid effects in the brain, such as analgesia.[1] It is used to treat opioid-induced constipation (OIC).[2]

Application

Methylnaltrexone bromide has been used as a drug to measure plasma protein binding (PPB), permeability (Pm) and the membrane coefficient (KIAM) for the prediction of blood brain barrier (BBB) penetration.[3] It is also used as a mu-opioid receptor (MOR) antagonist to abrogate morphine tolerance and opioid-induced hyperalgesia (OIH).[4]

Biochem/physiol Actions

Methylnaltrexone bromide is a narcotic antagonist.
Methylnaltrexone bromide is a narcotic antagonist. It is a peripheral mu-opiod receptor antagonist that cannot cross the blood-brain barrier. It reverses many opioid side-effects without interfering with pain relief.

Features and Benefits

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

STOT SE 2 Oral

target_organs

Gastrointestinal tract

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A Brokjaer et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 27(5), 693-704 (2015-03-27)
Opioid antagonists are increasingly used to abolish the gastrointestinal side effects of opioids. However, they can potentially interfere with local analgesia exerted via opioid receptors in the gut. Thus, in the current study we aimed to explore the effect of
Antonio Gatti et al.
Clinical drug investigation, 32(5), 293-301 (2012-03-15)
Opioids are one of the most widely used therapies for the palliative treatment of cancer pain; however, despite their proven analgesic efficacy, they are associated with several adverse effects. Associated with psychological distress and multiple concomitant clinical concerns, constipation is
Expanding LogP: Present possibilities
Vraka C, et al.
Nuclear Medicine and Biology, 58, 20-32 (2018)
Loss of mu-opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia
Corder G, et al.
Nature Medicine, 23(2), 164-164 (2017)
Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial
Yuan CS, et al.
JAMA : The Journal of the American Medical Association, 283(3), 367-372 (2000)

Articles

We offers many products related to opioid receptors for your research needs.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service